Cargando…
Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment
RATIONALE: Relapsed or refractory peripheral T-cell lymphomas are aggressive diseases. Pralatrexate is an antimetabolite. Hereby, we are reporting a pralatrexate induced durable response in a relapsed/refractory peripheral T-Cell lymphoma patient with a history of autologous stem cell transplantatio...
Autores principales: | Merdin, Alparslan, İskender, Dicle, Ulu, Bahar Uncu, Doğan, Mehmet, Çakar, Merih Kizil, Dal, Mehmet Sinan, Altuntaş, Fevzi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709046/ https://www.ncbi.nlm.nih.gov/pubmed/31348254 http://dx.doi.org/10.1097/MD.0000000000016482 |
Ejemplares similares
-
Latent tuberculosis in adult hematopoietic stem cell transplantation recipients: Clinical experience from a previously endemic population
por: Mert, Duygu, et al.
Publicado: (2022) -
Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience
por: BATGİ, Hikmettullah, et al.
Publicado: (2021) -
Molecular evaluation of mutations in acute myeloid leukemia patients from Turkey: A single-center study
por: Merdin, Alparslan, et al.
Publicado: (2021) -
Evaluation of HBV, HCV, and HIV seroprevalence in patients with plasma cell disorders
por: Mert, Duygu, et al.
Publicado: (2020) -
Analysis of pre-chemotherapy WBC, PLT, monocyte, hemoglobin, and MPV levels in acute myeloid leukemia patients with WT1, FLT3, or NPM gene mutations
por: Merdin, Alparslan, et al.
Publicado: (2020)